Back to search
FDAFDA · Food and drugs·Recall number D-0716-2022

Erythromycin Topical Gel USP, 2%, Net Wt 30 g tube, Rx only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, Distributed by: McKesson Corporation, dba Sky Packaging, 4971 Southridge Blvd., Suite 101, Memphis, TN 38141, NDC 63739-053-66.

Published February 23, 2022 · Recall initiated: February 7, 2022

Summary

FDA records drug Class II recall D-0716-2022, published February 23, 2022 and initiated February 7, 2022. Recalling firm: Teligent Pharma, Inc.; Status: Terminated; Reported quantity: 11040 tubes; Lot: Lot: 15724, Exp. 06/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teligent Pharma, Inc.
Distributor
Nationwide in the USA.
Lot
Lot: 15724, Exp. 06/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Erythromycin Topical Gel USP, 2%, Net Wt 30 g tube, Rx only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, Distributed by: McKesson Corporation, dba Sky Packaging, 4971 Southridge Blvd., Suite 101, Memphis, TN 38141, NDC 63739-053-66. recalled?

Yes. FDA published recall D-0716-2022 on February 23, 2022. Reported hazard: Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.

What should I do if I have this product?

Voluntary: Firm initiated · Letter